Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study

INTRODUCTION: Evidences of biologics-free disease control after discontinuing adalimumab (ADA) in rheumatoid arthritis (RA) patients in clinical practice have not been sufficiently investigated. Purpose of this study is to investigate whether disease activity score 28 (DAS28)- erythrocyte sedimentat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Shintaro, Saito, Kazuyoshi, Kubo, Satoshi, Fukuyo, Shunsuke, Mizuno, Yasushi, Iwata, Shigeru, Nawata, Masao, Sawamukai, Norifumi, Nakano, Kazuhisa, Yamaoka, Kunihiro, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978613/
https://www.ncbi.nlm.nih.gov/pubmed/24286472
http://dx.doi.org/10.1186/ar4315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978613/
https://www.ncbi.nlm.nih.gov/pubmed/24286472
http://dx.doi.org/10.1186/ar4315

Ejemplares similares